Publications by authors named "Brian D Hamman"

Claim this Profile
C
Correction to "PROTACs Targeting BRM (SMARCA2) Afford Selective Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models".
Michael Berlin, Jennifer Cantley, Mark Bookbinder, Elizabeth Bortolon, Fabio Broccatelli, Brian D Hamman

J Med Chem· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PROTACs Targeting BRM (SMARCA2) Afford Selective Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models.
Michael Berlin, Jennifer Cantley, Mark Bookbinder, Elizabeth Bortolon, Fabio Broccatelli, Brian D Hamman

J Med Chem· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers.
Jennifer Cantley, Xiaofen Ye, Emma Rousseau, Tom Januario, Brian D Hamman

Nat Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bicyclic Heterocyclic Replacement of an Aryl Amide Leading to Potent and Kinase-Selective Adaptor Protein 2-Associated Kinase 1 Inhibitors.
Richard A Hartz, Vijay T Ahuja, Susheel J Nara, C M Vijaya Kumar, Raju K V L P Manepalli, Brian D Hamman

J Med Chem· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery, Structure-Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain.
Richard A Hartz, Vijay T Ahuja, Susheel J Nara, C M Vijaya Kumar, Jeffrey M Brown, Brian D Hamman

J Med Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
Blake E Smith, Stephen L Wang, Saul Jaime-Figueroa, Alicia Harbin, Jing Wang, Brian D Hamman

Nat Commun· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and Characterization of Von Hippel-Lindau-Recruiting Proteolysis Targeting Chimeras (PROTACs) of TANK-Binding Kinase 1.
Andrew P Crew, Kanak Raina, Hanqing Dong, Yimin Qian, Jing Wang, Brian D Hamman

J Med Chem· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Daniel P Bondeson, Blake E Smith, George M Burslem, Alexandru D Buhimschi, John Hines, Brian D Hamman

Cell Chem Biol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain.
Walter Kostich, Brian D Hamman, Yu-Wen Li, Sreenivasulu Naidu, Kumaran Dandapani

J Pharmacol Exp Ther· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic deletion of Mst1 alters T cell function and protects against autoimmunity.
Konstantin V Salojin, Brian D Hamman, Wei Chun Chang, Kanchan G Jhaver, Amin Al-Shami

PLoS One· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation.
Nicole C Goodwin, Giovanni Cianchetta, Hugh A Burgoon, Jason Healy, Ross Mabon, Brian D Hamman

ACS Med Chem Lett· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.
Bryce A Harrison, Zheng Y Almstead, Hugh Burgoon, Michael Gardyan, Nicole C Goodwin, Brian D Hamman

ACS Med Chem Lett· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A high-throughput screen for receptor protein tyrosine phosphatase-gamma selective inhibitors.
Kingsley K Appiah, Walter A Kostich, Samuel W Gerritz, Yanling Huang, Brian D Hamman

J Biomol Screen· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profound obesity secondary to hyperphagia in mice lacking kinase suppressor of ras 2.
Jean-Pierre Revelli, Deon Smith, Jason Allen, Sabrina Jeter-Jones, Melanie K Shadoan, Brian D Hamman

Obesity (Silver Spring)· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma.
Bryce A Harrison, N Andrew Whitlock, Michael V Voronkov, Zheng Y Almstead, Kun-jian Gu, Brian D Hamman

J Med Chem· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A homogeneous G protein-coupled receptor ligand binding assay based on time-resolved fluorescence resonance energy transfer.
Liaoyuan A Hu, Tian Zhou, Brian D Hamman, Qingyun Liu

Assay Drug Dev Technol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases.
Steven M Rodems, Brian D Hamman, Christina Lin, Jane Zhao, Sundeep Shah

Assay Drug Dev Technol· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Binding of a Pleckstrin homology domain protein to phosphoinositide in membranes: a miniaturized FRET-based assay for drug screening.
Brian D Hamman, Brian A Pollok, Todd Bennett, Janet Allen, Roger Heim

J Biomol Screen· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis